Form 8-K - Current report:
SEC Accession No. 0001493152-22-034318
Filing Date
2022-12-02
Accepted
2022-12-02 16:31:28
Documents
14
Period of Report
2022-11-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39524
2 ex99-1.htm EX-99.1 21220
  Complete submission text file 0001493152-22-034318.txt   279237

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lixt-20221130.xsd EX-101.SCH 3990
4 XBRL DEFINITION FILE lixt-20221130_def.xml EX-101.DEF 26651
5 XBRL LABEL FILE lixt-20221130_lab.xml EX-101.LAB 36769
6 XBRL PRESENTATION FILE lixt-20221130_pre.xml EX-101.PRE 25275
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5423
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 221442421
SIC: 2834 Pharmaceutical Preparations